HRP20231191T1 - Postupak za proizvodnju n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida putem reakcije odgovarajućeg amina s 3-halo-propionilkloridom - Google Patents
Postupak za proizvodnju n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida putem reakcije odgovarajućeg amina s 3-halo-propionilkloridom Download PDFInfo
- Publication number
- HRP20231191T1 HRP20231191T1 HRP20231191TT HRP20231191T HRP20231191T1 HR P20231191 T1 HRP20231191 T1 HR P20231191T1 HR P20231191T T HRP20231191T T HR P20231191TT HR P20231191 T HRP20231191 T HR P20231191T HR P20231191 T1 HRP20231191 T1 HR P20231191T1
- Authority
- HR
- Croatia
- Prior art keywords
- reaction
- pyrimidin
- methoxy
- phenyl
- image
- Prior art date
Links
- RRMJMHOQSALEJJ-UHFFFAOYSA-N N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide Chemical compound CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1 RRMJMHOQSALEJJ-UHFFFAOYSA-N 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 150000001412 amines Chemical class 0.000 title 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 24
- 238000006243 chemical reaction Methods 0.000 claims 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 21
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 12
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 7
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- CFUNLIKOHNWOSD-UHFFFAOYSA-N N-(2-methoxy-4-morpholin-4-yl-5-nitrophenyl)formamide Chemical compound COC1=C(C=C(C(=C1)N1CCOCC1)[N+](=O)[O-])NC=O CFUNLIKOHNWOSD-UHFFFAOYSA-N 0.000 claims 5
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 5
- 229940093499 ethyl acetate Drugs 0.000 claims 5
- 235000019439 ethyl acetate Nutrition 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 5
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 5
- 235000011009 potassium phosphates Nutrition 0.000 claims 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- GOZZBVSFYMEUEJ-UHFFFAOYSA-N 1-[2-(2-methoxy-4-morpholin-4-yl-5-nitroanilino)pyrimidin-4-yl]-3-phenylpyrazole-4-carbaldehyde Chemical compound COC1=C(C=C(C(=C1)N1CCOCC1)[N+](=O)[O-])NC1=NC=CC(=N1)N1N=C(C(=C1)C=O)C1=CC=CC=C1 GOZZBVSFYMEUEJ-UHFFFAOYSA-N 0.000 claims 4
- NYZJOVYDUQTQEY-UHFFFAOYSA-N CS(=O)(=O)C1=NC=CC(=N1)N1N=C(C(=C1)C=O)C1=CC=CC=C1 Chemical compound CS(=O)(=O)C1=NC=CC(=N1)N1N=C(C(=C1)C=O)C1=CC=CC=C1 NYZJOVYDUQTQEY-UHFFFAOYSA-N 0.000 claims 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229940043279 diisopropylamine Drugs 0.000 claims 4
- 239000007800 oxidant agent Substances 0.000 claims 4
- 239000001488 sodium phosphate Substances 0.000 claims 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims 3
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 claims 3
- OEBMPNVNFQOTEH-UHFFFAOYSA-N 3-N-[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]-4-methoxy-6-morpholin-4-ylbenzene-1,3-diamine Chemical class CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC1=CC(=C(C=C1OC)N1CCOCC1)N)C1=CC=CC=C1 OEBMPNVNFQOTEH-UHFFFAOYSA-N 0.000 claims 3
- DFOHHQRGDOQMKG-UHFFFAOYSA-N 4-chloro-2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC(Cl)=N1 DFOHHQRGDOQMKG-UHFFFAOYSA-N 0.000 claims 3
- BWVZLXTZQHILRC-UHFFFAOYSA-N 4-chloro-2-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=NC=CC(Cl)=N1 BWVZLXTZQHILRC-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 3
- 230000022244 formylation Effects 0.000 claims 3
- 238000006170 formylation reaction Methods 0.000 claims 3
- 229940043265 methyl isobutyl ketone Drugs 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 230000003647 oxidation Effects 0.000 claims 3
- 238000007254 oxidation reaction Methods 0.000 claims 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012312 sodium hydride Substances 0.000 claims 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims 3
- YMIYWAWQAYMLPZ-UHFFFAOYSA-N 2-methoxy-4-morpholin-4-yl-5-nitroaniline Chemical compound COC1=C(N)C=C(C(=C1)N1CCOCC1)[N+](=O)[O-] YMIYWAWQAYMLPZ-UHFFFAOYSA-N 0.000 claims 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims 2
- VHKHOJXOHUOQPJ-UHFFFAOYSA-N 4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]-N-(2-methoxy-4-morpholin-4-yl-5-nitrophenyl)pyrimidin-2-amine Chemical compound CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N1CCOCC1)OC)C1=CC=CC=C1 VHKHOJXOHUOQPJ-UHFFFAOYSA-N 0.000 claims 2
- OCCFXKQCKSLEII-UHFFFAOYSA-N 5-phenyl-1h-pyrazole-4-carbaldehyde Chemical compound C1=NNC(C=2C=CC=CC=2)=C1C=O OCCFXKQCKSLEII-UHFFFAOYSA-N 0.000 claims 2
- SSPFYLFMLDFZIL-UHFFFAOYSA-N CSC1=NC=CC(=N1)N1N=C(C(=C1)C=O)C1=CC=CC=C1 Chemical compound CSC1=NC=CC(=N1)N1N=C(C(=C1)C=O)C1=CC=CC=C1 SSPFYLFMLDFZIL-UHFFFAOYSA-N 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- WRGYGMMDJMUMIB-UHFFFAOYSA-N ClC1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N1CCOCC1)OC Chemical compound ClC1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N1CCOCC1)OC WRGYGMMDJMUMIB-UHFFFAOYSA-N 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 2
- 150000004703 alkoxides Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 claims 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 2
- 229960004132 diethyl ether Drugs 0.000 claims 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 2
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 2
- 229940011051 isopropyl acetate Drugs 0.000 claims 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 235000011181 potassium carbonates Nutrition 0.000 claims 2
- 239000012286 potassium permanganate Substances 0.000 claims 2
- 235000017550 sodium carbonate Nutrition 0.000 claims 2
- 235000011008 sodium phosphates Nutrition 0.000 claims 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims 2
- LRGBDJBDJXZTTD-UHFFFAOYSA-N 1h-pyrazole-4-carbaldehyde Chemical compound O=CC=1C=NNC=1 LRGBDJBDJXZTTD-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims 1
- 239000003350 kerosene Substances 0.000 claims 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 239000003208 petroleum Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000012279 sodium borohydride Substances 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims 1
- -1 sodium triacetoxyborohydride Chemical compound 0.000 claims 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims 1
- 239000008096 xylene Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/22—Tin compounds
- C07F7/2284—Compounds with one or more Sn-N linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Claims (12)
1. Postupak za proizvodnju N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida:
[image]
ili njegove farmaceutski prihvatljive soli,
naznačen time, da postupak obuhvaća
(a) reakciju N1-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)-6-metoksi-4-morfolinobenzen-1,3-diamina:
[image]
sa spojem Formule 4 u svrhu dobivanja spoja Formule 2; i
(b) reakciju spoja Formule 2 s bazom u svrhu dobivanja N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida:
[image]
[image]
[image]
gdje, X je halogen.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da:
(i) se reakcija iz Koraka (a) provodi u prisutnosti jedne ili više baza odabranih iz skupine koju čine kalijev terc-butoksid, natrijev hidroksid, kalijev hidroksid, litijev hidroksid, natrijev hidrid, natrijev karbonat, natrijev bikarbonat, kalijev karbonat, kalijev fosfat, natrijev fosfat, 1,8-diazabiciklo[5.4.0]undek-7-en, 1,4-diazabiciklo[2.2.2]oktan, 1,5-diazabiciklo[4.3.0]non-5-en, piridin, trietilamin, diizopropilamin, i diizopropiletilamin; ili
(ii) se reakcija iz Koraka (a) provodi u prisutnosti otapala odabranog iz skupine koju čine acetonitril, metiletilketon, aceton, metilizobutilketon, diklorometan, dikloroetan, dimetilformamid, dimetilacetamid, dimetilsulfoksid, tetrahidrofuran, C1 ~ C5 alkohol, toluen, etilacetat, izopropilacetat, dietileter, voda i njihova mješavina, a opcionalno pritom se otapalo bira iz skupine koju čine acetonitril, tetrahidrofuran, metiletilketon, aceton, diklorometan, voda i njihova mješavina; ili
(iii) je baza koja se koristi u Koraku (b), jedna ili više odabranih iz skupine koju čine kalijev terc-butoksid, natrijev hidroksid, kalijev hidroksid, litijev hidroksid, natrijev hidrid, natrijev karbonat, natrijev bikarbonat, kalijev karbonat, kalijev fosfat, natrijev fosfat, 1,8-diazabiciklo[5.4.0]undek-7-en, 1,4-diazabiciklo[2.2.2]oktan, 1,5-diazabiciklo[4.3.0]non-5-en, piridin, trietilamin, diizopropilamin, i diizopropiletilamin, a opcionalno pritom baza je jedna ili više odabranih iz skupine koju čine natrijev hidroksid, trietilamin, i diizopropilamin; ili
(iv) se reakcija iz Koraka (b) provodi u prisutnosti otapala odabranog iz skupine koju čine acetonitril, metiletilketon, aceton, metilizobutilketon, diklorometan, dikloroetan, dimetilformamid, dimetilacetamid, dimetilsulfoksid, tetrahidrofuran, C1 ~ C5 alkohol, toluen, etilacetat, izopropilacetat, dietileter, voda i njihova mješavina, a opcionalno pritom se otapalo bira iz skupine koju čine acetonitril, tetrahidrofuran, metiletilketon, aceton, diklorometan, voda i njihova mješavina; ili
(v) se Korak (a) i Korak (b) provode putem reakcije u jednom reaktoru.
3. Postupak prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time, da se N1-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)-6-metoksi-4-morfolinobenzen-1,3-diamin u Koraku (a) dobiva putem postupka koji obuhvaća
(i) reakciju 4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)-N-(2-metoksi-4-morfolino-5-nitrofenil)pirimidin-2-amina:
[image]
s kloridom u prisutnosti klorovodične kiseline u svrhu dobivanja kompleksa Formule 5, i
(ii) reakciju kompleksa Formule 5 s bazom u svrhu dobivanja N1-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)-6-metoksi-4-morfolinobenzen-1,3-diamina:
[image]
.
4. Postupak prema patentnom zahtjevu 3, naznačen time, da se reakcija iz Koraka (i) provodi u prisutnosti jednog ili više otapala odabranih iz skupine koju čine voda, C1 ~ C10 alkohol, diklorometan, tetrahidrofuran, acetonitril, i etilacetat.
5. Postupak prema patentnom zahtjevu 3, naznačen time, da je baza koja se koristi u Koraku (ii) jedna ili više odabranih iz skupine koju čine natrijev hidroksid, kalijev hidroksid, natrijev karbonat, natrijev bikarbonat, kalijev karbonat, kalijev fosfat, i natrijev fosfat.
6. Postupak prema patentnom zahtjevu 3, naznačen time, da se 4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)-N-(2-metoksi-4-morfolino-5-nitrofenil)pirimidin-2-amin dobiva putem reakcije 1-(2-((2-metoksi-4-morfolino-5-nitrofenil)amino)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehida:
[image]
s dimetilaminom ili njegovom soli.
7. Postupak prema patentnom zahtjevu 6, naznačen time, da:
(i) se reakcija provodi u prisutnosti jednog ili više redukcijskih sredstava odabranih iz skupine koju čine natrijev triacetoksiborohidrid, natrijev cijanoborohidrid, i natrijev borohidrid; ili
(ii) se 1-(2-((2-metoksi-4-morfolino-5-nitrofenil)amino)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehid dobiva putem reakcije 4-kloro-N-(2-metoksi-4-morfolino-5-nitrofenil)pirimidin-2-amina:
[image]
s 3-fenil-1H-pirazol-4-karbaldehidom:
[image]
8. Postupak prema patentnom zahtjevu 7(ii), naznačen time, da se 4-kloro-N-(2-metoksi-4-morfolino-5-nitrofenil)pirimidin-2-amin dobiva putem reakcije N-(2-metoksi-4-morfolino-5-nitrofenil)formamida:
[image]
s 4-kloro-2-(metilsulfonil)pirimidinom:
[image]
opcionalno:
a. gdje se N-(2-metoksi-4-morfolino-5-nitrofenil)formamid dobiva putem izvođenja formilacije 2-metoksi-4-morfolino-5-nitroanilina:
[image]
ili
b. gdje se N-(2-metoksi-4-morfolino-5-nitrofenil)formamid dobiva putem izvođenja formilacije 2-metoksi-4-morfolino-5-nitroanilina, i gdje se formilacija provodi s mješavinom octene kiseline i mravlje kiseline; ili
c. gdje se 4-kloro-2-(metilsulfonil)pirimidin dobiva putem izvođenja oksidacije 4-kloro-2-(metiltio)pirimidina:
[image]
ili
d. gdje se 4-kloro-2-(metilsulfonil)pirimidin dobiva putem izvođenja oksidacije 4-kloro-2-(metiltio)pirimidina, i gdje se oksidacija provodi s jednim ili više oksidacijskih sredstava odabranih iz skupine koju čine kalijev permanganat, kromna kiselina, kisik, vodikov peroksid, i 3-kloroperbenzojeva kiselina.
9. Postupak prema patentnom zahtjevu 6, naznačen time, da se 1-(2-((2-metoksi-4-morfolino-5-nitrofenil)amino)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehid dobiva putem reakcije N-(2-metoksi-4-morfolino-5-nitrofenil)formamida s 1-(2-(metilsulfonil)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehidom:
[image]
opcionalno:
a. pri čemu se reakcija provodi u prisutnosti jedne ili više baza odabranih iz skupine koju čine natrijev C1 ~ C6 alkoksid, kalijev C1 ~ C6 alkoksid, natrijev karbonat, kalijev karbonat, i kalijev fosfat; ili
b. pri čemu se reakcija provodi u prisutnosti jednog ili više otapala odabranih iz skupine koju čine dimetilformamid, dimetilacetamid, diklorometan, dimetilsulfoksid, tetrahidrofuran, heksametilfosforamid, C1 ~ C5 alkohol, dietileter, etilacetat, acetonitril, i aceton; ili
c. pri čemu se 1-(2-(metilsulfonil)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehid dobiva putem reakcije 1-(2-(metiltio)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehida:
[image]
s oksidacijskim sredstvom.
10. Postupak prema patentnom zahtjevu 6, naznačen time, da se 1-(2-((2-metoksi-4-morfolino-5-nitrofenil)amino)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehid dobiva putem reakcije N-(2-metoksi-4-morfolino-5-nitrofenil)formamida s 1-(2-(metilsulfonil)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehidom, i gdje se 1-(2-(metilsulfonil)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehid dobiva putem reakcije 1-(2-(metiltio)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehida s oksidacijskim sredstvom:
(i) gdje je oksidacijsko sredstvo jedno ili više odabranih iz skupine koju čine kalijev permanganat, kromna kiselina, kisik, vodikov peroksid, i 3-kloroperbenzojeva kiselina; ili
(ii) gdje se reakcija provodi u prisutnosti jednog ili više otapala odabranih iz skupine koju čine C1 ~ C5 alkohol, ugljikov tetraklorid, kloroform, diklorometan, aceton, metiletilketon, metilizobutilketon, cikloheksanon, pentan, heksan, heptan, oktan, nonan, dekan, undekan, dodekan, cikloheksan, petrolej eter, kerozin, toluen, ksilen, mezitilen, i benzen; ili
(iii) gdje se 1-(2-(metiltio)pirimidin-4-il)-3-fenil-1H-pirazol-4-karbaldehid dobiva putem reakcije 4-kloro-2-(metiltio)pirimidina s 3-fenil-1H-pirazol-4-karbaldehidom.
11. Postupak prema patentnom zahtjevu 10(iii), naznačen time, da:
(i) se reakcija provodi u prisutnosti jedne ili više baza odabranih iz skupine koju čine kalijev terc-butoksid, natrijev hidroksid, kalijev hidroksid, natrijev hidrid, natrijev karbonat, kalijev karbonat, kalijev fosfat, natrijev fosfat, 1,8-diazabiciklo[5.4.0]undek-7-en, 1,4-diazabiciklo[2.2.2]oktan, 1,5-diazabiciklo[4.3.0]non-5-en, piridin, trietilamin, diizopropilamin, i diizopropiletilamin; ili
(ii) se reakcija provodi u prisutnosti jednog ili više otapala odabranih iz skupine koju čine diklorometan, dikloroetan, dimetilformamid, dimetilacetamid, dimetilsulfoksid, tetrahidrofuran, C1 ~ C5 alkohol, etilacetat, aceton, metiletilketon, acetonitril, i toluen.
12. Spoj, naznačen time, da je predstavljen Formulom 2, ili soli od toga:
[image]
u kojoj, X je halogen.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170096212 | 2017-07-28 | ||
PCT/KR2018/008379 WO2019022485A1 (en) | 2017-07-28 | 2018-07-25 | IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES |
EP18837360.9A EP3658552B1 (en) | 2017-07-28 | 2018-07-25 | Process for preparing n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide by reacting the corresponding amine with a 3-halo-propionyl chloride |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231191T1 true HRP20231191T1 (hr) | 2024-02-02 |
Family
ID=65040211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231191TT HRP20231191T1 (hr) | 2017-07-28 | 2018-07-25 | Postupak za proizvodnju n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida putem reakcije odgovarajućeg amina s 3-halo-propionilkloridom |
Country Status (31)
Country | Link |
---|---|
US (4) | US10889578B2 (hr) |
EP (1) | EP3658552B1 (hr) |
JP (2) | JP7228562B2 (hr) |
KR (1) | KR20190013553A (hr) |
CN (2) | CN116987112A (hr) |
AU (2) | AU2018308038B2 (hr) |
BR (1) | BR112020001278A2 (hr) |
CA (1) | CA3070069C (hr) |
CO (1) | CO2020000374A2 (hr) |
DK (1) | DK3658552T3 (hr) |
EA (1) | EA202090383A1 (hr) |
ES (1) | ES2962961T3 (hr) |
FI (1) | FI3658552T3 (hr) |
HR (1) | HRP20231191T1 (hr) |
HU (1) | HUE063533T2 (hr) |
IL (2) | IL271973B (hr) |
LT (1) | LT3658552T (hr) |
MA (1) | MA49700B1 (hr) |
MD (1) | MD3658552T2 (hr) |
MX (1) | MX2022008743A (hr) |
NZ (1) | NZ761156A (hr) |
PH (1) | PH12020500059A1 (hr) |
PL (1) | PL3658552T3 (hr) |
PT (1) | PT3658552T (hr) |
RS (1) | RS64654B1 (hr) |
SA (1) | SA520411112B1 (hr) |
SG (1) | SG11201913517UA (hr) |
SI (1) | SI3658552T1 (hr) |
UA (1) | UA125317C2 (hr) |
WO (1) | WO2019022485A1 (hr) |
ZA (1) | ZA202001250B (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI3658552T3 (fi) | 2017-07-28 | 2023-11-16 | Yuhan Corp | Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa |
WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
US11850248B2 (en) * | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
US11780824B2 (en) * | 2020-12-16 | 2023-10-10 | Scinopharm Taiwan, Ltd. | Process for preparing osimertinib or a salt thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
ATE370123T1 (de) | 2001-11-27 | 2007-09-15 | Wyeth Corp | 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2008520612A (ja) | 2004-11-24 | 2008-06-19 | ノバルティス アクチエンゲゼルシャフト | JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ |
US20060270600A1 (en) | 2005-05-26 | 2006-11-30 | Eisuke Mekada | Anti-cancer agents |
TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
EP2684874B1 (en) | 2006-10-23 | 2017-05-17 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors |
TW200840581A (en) | 2007-02-28 | 2008-10-16 | Astrazeneca Ab | Novel pyrimidine derivatives |
WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
NZ599826A (en) | 2009-10-12 | 2014-08-29 | Myrexis Inc | Amino-pyrimidine compounds as inhibitors of ikk epsilon and/or tbk1 |
KR101663637B1 (ko) | 2009-11-13 | 2016-10-07 | 제노스코 | 키나아제 억제제 |
CA2782684C (en) | 2009-12-04 | 2018-09-04 | Mustapha Haddach | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
EA022623B1 (ru) | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
ES2635713T3 (es) | 2010-11-01 | 2017-10-04 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
WO2012082689A1 (en) | 2010-12-13 | 2012-06-21 | Array Biopharma Inc. | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
CN105348266B (zh) * | 2011-07-27 | 2018-04-10 | 阿斯利康(瑞典)有限公司 | 取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐 |
WO2013096642A1 (en) | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
PL2797927T3 (pl) | 2011-12-30 | 2019-12-31 | Hanmi Pharm. Co., Ltd. | Pochodne tieno[3,2-d]pirymidyny wykazujące działanie hamujące kinazy białkowe |
CN104860891B (zh) | 2014-02-25 | 2017-06-30 | 上海海雁医药科技有限公司 | 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物 |
CN106687457B (zh) | 2014-05-13 | 2020-01-10 | 阿里亚德医药股份有限公司 | 用于激酶抑制的杂芳基化合物 |
CN111875585B (zh) | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | 一类激酶抑制剂 |
PT3207035T (pt) * | 2014-10-13 | 2020-02-19 | Yuhan Corp | Compostos e composições para modular actividades da cinase do mutante de egfr |
CN104788427B (zh) | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
AR102263A1 (es) | 2015-10-14 | 2017-02-15 | Yuhan Corp | Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante |
DE102017212159A1 (de) | 2017-07-14 | 2019-01-17 | Krones Aktiengesellschaft | Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden |
PT3658547T (pt) | 2017-07-28 | 2023-10-20 | Yuhan Corp | Processo de preparação de n -(5 -(4 -(4 -formil -3- fenil- 1h -pirazol- 1 -il)pirimidin -2- ilamino) -4 -metoxi 2- morfolinofenil) acrilamida |
FI3658552T3 (fi) | 2017-07-28 | 2023-11-16 | Yuhan Corp | Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa |
CN108826170A (zh) | 2018-06-26 | 2018-11-16 | 深圳市远润欣电子有限公司 | 局部全般照明的模式、控制方法及台灯 |
-
2018
- 2018-07-25 FI FIEP18837360.9T patent/FI3658552T3/fi active
- 2018-07-25 WO PCT/KR2018/008379 patent/WO2019022485A1/en active Application Filing
- 2018-07-25 MA MA49700A patent/MA49700B1/fr unknown
- 2018-07-25 MX MX2022008743A patent/MX2022008743A/es unknown
- 2018-07-25 SI SI201830998T patent/SI3658552T1/sl unknown
- 2018-07-25 SG SG11201913517UA patent/SG11201913517UA/en unknown
- 2018-07-25 LT LTEPPCT/KR2018/008379T patent/LT3658552T/lt unknown
- 2018-07-25 CA CA3070069A patent/CA3070069C/en active Active
- 2018-07-25 BR BR112020001278-5A patent/BR112020001278A2/pt unknown
- 2018-07-25 IL IL271973A patent/IL271973B/en unknown
- 2018-07-25 AU AU2018308038A patent/AU2018308038B2/en active Active
- 2018-07-25 PT PT188373609T patent/PT3658552T/pt unknown
- 2018-07-25 KR KR1020180086376A patent/KR20190013553A/ko active IP Right Grant
- 2018-07-25 CN CN202310702453.8A patent/CN116987112A/zh active Pending
- 2018-07-25 JP JP2020504203A patent/JP7228562B2/ja active Active
- 2018-07-25 RS RS20230834A patent/RS64654B1/sr unknown
- 2018-07-25 HR HRP20231191TT patent/HRP20231191T1/hr unknown
- 2018-07-25 HU HUE18837360A patent/HUE063533T2/hu unknown
- 2018-07-25 UA UAA202001303A patent/UA125317C2/uk unknown
- 2018-07-25 ES ES18837360T patent/ES2962961T3/es active Active
- 2018-07-25 DK DK18837360.9T patent/DK3658552T3/da active
- 2018-07-25 PL PL18837360.9T patent/PL3658552T3/pl unknown
- 2018-07-25 MD MDE20200593T patent/MD3658552T2/ro unknown
- 2018-07-25 EP EP18837360.9A patent/EP3658552B1/en active Active
- 2018-07-25 CN CN201880048638.9A patent/CN111315742B/zh active Active
- 2018-07-25 EA EA202090383A patent/EA202090383A1/ru unknown
- 2018-07-25 NZ NZ761156A patent/NZ761156A/en unknown
- 2018-07-25 US US16/633,684 patent/US10889578B2/en active Active
-
2020
- 2020-01-07 PH PH12020500059A patent/PH12020500059A1/en unknown
- 2020-01-15 CO CONC2020/0000374A patent/CO2020000374A2/es unknown
- 2020-01-21 SA SA520411112A patent/SA520411112B1/ar unknown
- 2020-02-27 ZA ZA2020/01250A patent/ZA202001250B/en unknown
- 2020-12-08 US US17/115,037 patent/US11286253B2/en active Active
-
2022
- 2022-03-25 US US17/704,718 patent/US11708362B2/en active Active
- 2022-04-24 IL IL292429A patent/IL292429B2/en unknown
- 2022-05-03 AU AU2022202936A patent/AU2022202936B2/en active Active
- 2022-11-18 JP JP2022184867A patent/JP2023027091A/ja active Pending
-
2023
- 2023-06-02 US US18/328,267 patent/US20230312545A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231191T1 (hr) | Postupak za proizvodnju n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida putem reakcije odgovarajućeg amina s 3-halo-propionilkloridom | |
ES2524045T3 (es) | Nuevas amidas y tioamidas heteroaromáticas como plaguicidas | |
SG174250A1 (en) | 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents | |
WO2015057945A1 (en) | Hepatitis b viral assembly effectors | |
PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
WO2017133670A1 (en) | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza | |
PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
PE20121438A1 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a | |
JP2023027091A5 (hr) | ||
CN101497601B (zh) | 伊马替尼的合成方法 | |
WO2017133657A1 (en) | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza | |
BR112020007684A2 (pt) | composto heterocíclico como um inibidor de proteína quinase | |
AU2023251449A1 (en) | Amine-substituted heterocyclic compounds as EHMT2 inhibitors and derivatives thereof | |
HRP20220848T1 (hr) | Intermedijeri korisni za sintezu derivata aminopirimidina, postupak za njihovu proizvodnju, i postupak za proizvodnju derivata aminopirimidina koji ih koriste | |
ES2354551B1 (es) | Bibliotecas de n-(1-fenil-2-oxo-3-piperidil)sulfonamidas para la identificación de actividad biológica y farmacológica. | |
HRP20160144T1 (hr) | Derivati etinila kao modulatori receptora metabotropskih glutamata | |
ES2567828T3 (es) | Derivados 2-aminopirimidina útiles como inhibidores de JNK | |
Dai et al. | Efficient synthesis of thieno [2, 3-d] pyrimidin-4 (3 H)-ones by a sequential aza-Wittig reaction/base catalyzed cyclization | |
JP2013216579A (ja) | 三置換インダゾールアクリル酸アミド誘導体の製造方法 | |
KR20110073757A (ko) | 피리미딘 유도체의 제조방법 | |
GB2532178A (en) | Antiviral compounds | |
TH94315B (th) | สารประกอบต่าง ๆ ซึ่งเพิ่มฤทธิ์หน่วยรับความรู้สึก ampa และการใช้สารเหล่านั้นในการแพทย์ |